The next battle in the never-ending war over Aduhelm

Now, it seems, the only way drug makers and patient advocates can reverse this decision is to go to the courts. Biogen and Eli Lilly, both of which would be impacted by Medicare’s decision, have seriously hinted they plan to sue. And that potential lawsuit could challenge not just the Aduhelm decision, but Medicare’s ability to require additional clinical trials writ large.